Transforming access: the power of patient-centricity in rare disease
Dana Vigier from Alexion considers the challenges facing rare disease treatment and the importance of patient-centricity to improve outcomes
21 May 2024Latest Issues
view moreTrending
Psychoactives in mental health treatment
Kabir Nath from Compass Pathways explores the need for new treatments in the mental health space, as well as assessing whether psychoactives could be the way forward
21 May 2024
Psychedelic medicines and the treatment of neurological conditions
Rob Conley from Beckley Psytech tells Pharmafile about the use of psychedelic medicine for the treatment of psychiatric and neurological conditions, and how this field could develop in the future
21 May 2024
Advancing treatment options for rare disease patients
Chris Moore from Veeva Europe explores how companies are overcoming challenges to develop, launch and educate on new rare disease medicines faster
21 May 2024
Reducing unintended pregnancy rates: how innovation in contraception can drive generational change
Dr Charlotte Owens from Organon explores the impact of innovations in contraception and how this can reduce unintended pregnancy rates
21 May 2024
International Women’s Day remains a key platform to keep inspiring inclusive, innovative healthcare
Frances Ramsay from InnoScot Health discusses the way forward in closing the gender health gap
21 May 2024Rare Diseases
Addressing orphan, rare and paediatric drug development through collaborative partnerships
Nazim Kanji and Huw Jones from Quotient Sciences consider orphan drug development and the benefit of CRO/CDMO collaboration, specifically in terms of paediatric rare diseases
Rare Diseases, 21 May 2024
Reimagining the clinical trial paradigm for rare disease patients
Elizabeth Sachnoff from Propharma considers the landscape of clinical trials for rare diseases, and how these could be improved
Rare Diseases, 21 May 2024
Overcoming obstacles in rare disease treatment
Dan Williams from SynaptixBio considers the problems facing the ongoing treatment of rare diseases, as well as how the pharma industry is moving forwards in their treatment
Rare Diseases, 21 May 2024Transforming access: the power of patient-centricity in rare disease
Dana Vigier from Alexion considers the challenges facing rare disease treatment and the importance of patient-centricity to improve outcomes
Rare Diseases, 21 May 2024Advancing treatment options for rare disease patients
Chris Moore from Veeva Europe explores how companies are overcoming challenges to develop, launch and educate on new rare disease medicines faster
Rare Diseases, 21 May 2024
Rising to the unique challenges of rare diseases
Aaron Bean at Veeva explores the challenges of rare diseases: With up to 30 million people in EU living with rare diseases, Veeva discusses the challenges facing these rare diseases
Rare Diseases, 1 December 2022Infectious Diseases
The AI frontier: transforming immunotherapy with intelligent drug discovery
Vicky Qu at BioMap considers the use of artificial intelligence in immuno-oncology and how its use can improve conventional drug discover y processes
Oncology, 1 October 2023
Repairing not destroying: the future of targeted cancer drug design
Lukasz Jaremko from King Abdullah University of Science and Technology, Saudi Arabia explains how using nuclear magnetic resonance to study the dynamics of epigenetic targets may enable drug development that does not kill but resets cancer cells to a benign state
Oncology, 1 October 2023
To achieve diversity in clinical trials, patient-led drug development is key
Amy McKee from Parexel considers the need for diversity in oncology clinical trials in order to fully realise the potential of personalised medicine
Oncology, 1 October 2023
The changing treatment landscape for follicular lymphoma
Dr Mitchell Smith and Dr Julie Dodds tell Pharmafile about recent R&D in the field of blood cancers including follicular lymphoma
Oncology, 1 October 2023
Prostate cancer: new screening measures and decreasing mortality rates
Professor Hendrik van Poppel talks to Pharmafile about new campaigns to improve prostate cancer screening, the current standard-of-care treatments and what obstacles still need to be addressed in treatment
Oncology, 1 October 2023Dermatology
Scratching the surface of eczema care in the UK
Pharmafilespeaks to Allergy UK: Allergy UK explores the future of eczema diagnosis, treatment, and support
Dermatology, 1 December 2021
Dermatologically speaking: Finding new treatments for women
Organon discusses the ways in which women's skin conditions can be managed
Dermatology, 1 December 2021
Insight and oversight: Making the most of virtual platforms in dermatology
FIDE discuss the need for communication between patients and their HCPs, specifically with virtual platforms in mind, and how this can improve dermatology care
Dermatology, 1 December 2021
“The pain keeps me awake at night. I can’t cope with this anymore”
There have been significant advances in dermatological care, this article explores this as well as looking forward to what still needs to be done
Dermatology, 1 December 2021
Supporting dermatology and oncology services to build back better post-COVID-19
The COVID-19 pandemic has been challenging service-wide for the NHS, but the pharma industry can support patients and the NHS going forward
Dermatology, 1 December 2021Pain
Medical cannabis - The inhaled answer to cancer and non-cancer pain?
Pharmafile speaks to Sapphire Clinics: Sapphire Clinics discuss the benefits of medical cannabis for pain management and how this has changed in the last decade
31 May 2022
Embracing transdermal technologies
Pharmafile speaks to Futura for their insights into the effective delivery of drugs for pain management and alternative technologies
31 May 2022
Pain management and pharmaceutical compounding
Pain management is key for both patient and HCP, but how can compounding medication aid in treatment?
31 May 2022
Pharmafile
Therapeutic areas in focus